CanSino Biologics (), often abbreviated as CanSinoBIO, is a Chinese vaccine company.

History

CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua. In July 2018, it filed an application to list on the

Hong Kong Stock Exchange The Stock Exchange of Hong Kong (SEHK, also known as Hong Kong Stock Exchange) is a stock exchange based in Hong Kong. As of the end of 2020, it has 2,538 listed companies with a combined market capitalization of HK$47 trillion. It is repor ...

. It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017. In August 2020, it completed a secondary offering on

Shanghai Stock Exchange The Shanghai Stock Exchange (SSE) is a stock exchange based in the city of Shanghai, China. It is one of the three stock exchanges operating independently in mainland China, the others being the Beijing Stock Exchange and the Shenzhen Stock Exc ...

's STAR market where it raised 5.2 billion yuan (US$750 million).

Vaccines

The company has a portfolio of vaccines under research including

Ad5-EBOV Ebola vaccines are vaccines either approved or in development to prevent Ebola. As of 2022, there are only vaccines against the Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019. It had bee ...

to prevent

Ebola Ebola, also known as Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF), is a viral hemorrhagic fever in humans and other primates, caused by ebolaviruses. Symptoms typically start anywhere between two days and three weeks after becom ...

and

Ad5-nCoV AD5-nCOV, trade-named Convidecia, is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics. It conducted its Phase III trials in Argentina, Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants. I ...

for COVID-19. The company has previously collaborated with the National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.

COVID-19 vaccine development

AD5-nCOV, trade-named Convidecia, is a single-dose

viral vector Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells. This process can be performed inside a living organism (''in vivo'') or in cell culture (''in vitro''). Viruses have evolved specialized molecul ...

COVID-19 vaccine A COVID19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 ( COVID19). Prior to the COVID19 pandemic, an e ...

developed by CanSino. Since late 2020, it has been in Phase III trials in Chile, Mexico, Pakistan, Russia, and Saudi Arabia with 40,000 participants. In February 2021, global data from Phase III trials and 101 COVID cases showed that the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease. It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial. Its single-dose regimen and normal refrigerator storage requirement make it a favorable vaccine option for many countries. It is currently under evaluation for emergency use listing by the WHO. In April 2021, CanSino Biologics has begun clinical trials for Covid-19, a vaccine that may be administered by inhalation rather than injection. Convidecia is approved for use by some countries in Asia, Europe, and Latin America. Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China, Malaysia, Mexico, and Pakistan.

Investors

CanSino Biologics investors included

Lilly Asia Ventures Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel ...

, Qiming Venture Partners and

SDIC Fund Management State Development and Investment Corporation (SDIC) (国家开发投资公司) is the largest state-owned investment holding company in China. It was established on 5 May 1995. SDIC's industrial investment mainly goes to power generation, coal m ...

References

{{authority control Chinese brands Chinese companies established in 2009 Companies based in Tianjin Pharmaceutical companies of China Vaccine producers COVID-19 vaccine producers

History

Vaccines

COVID-19 vaccine development

Investors

See also

References